瑞博生物-B(06938)：核心产品VORTOSIRAN完成针对SPAF适应症的 2b期临床试验申请递交

智通财经04-14

智通财经APP讯，瑞博生物-B(06938)发布公告，本公司核心产品Vortosiran (RBD4059)已成功向欧洲药品管理局(EMA)递交针对心房颤动患者卒中预防 (SPAF)的2b期临床试验申请(CTA)，这是全球首个于心房颤动(AF)临床试验中的小干扰核酸(siRNA) XI凝血因子(FXI)抑制剂，标志着siRNA药物在抗凝疗法领域临床开发的重要里程碑。本研究为本公司涵盖多个已规划的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2627464707?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-14 08:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627464707","market":"sh","top_or_hot":-1,"title":"瑞博生物-B(06938)：核心产品VORTOSIRAN完成针对SPAF适应症的 2b期临床试验申请递交","media":"智通财经","content":"<div>\n<p>智通财经APP讯，瑞博生物-B(06938)发布公告，本公司核心产品Vortosiran (RBD4059)已成功向欧洲药品管理局(EMA)递交针对心房颤动患者卒中预防 (SPAF)的2b期临床试验申请(CTA)，这是全球首个于心房颤动(AF)临床试验中的小干扰核酸(siRNA) XI凝血因子(FXI)抑制剂，标志着siRNA药物在抗凝疗法领域临床开发的重要里程碑。本研究为本公司涵盖多个已规划的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1428030.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>瑞博生物-B(06938)：核心产品VORTOSIRAN完成针对SPAF适应症的 2b期临床试验申请递交</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n瑞博生物-B(06938)：核心产品VORTOSIRAN完成针对SPAF适应症的 2b期临床试验申请递交\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-14 08:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1428030.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，瑞博生物-B(06938)发布公告，本公司核心产品Vortosiran (RBD4059)已成功向欧洲药品管理局(EMA)递交针对心房颤动患者卒中预防 (SPAF)的2b期临床试验申请(CTA)，这是全球首个于心房颤动(AF)临床试验中的小干扰核酸(siRNA) XI凝血因子(FXI)抑制剂，标志着siRNA药物在抗凝疗法领域临床开发的重要里程碑。本研究为本公司涵盖多个已规划的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1428030.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1428030.html","article_id":"2627464707","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627464707","pubTimestamp":1776124949,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，瑞博生物-B 发布公告，本公司核心产品Vortosiran 已成功向欧洲药品管理局递交针对心房颤动患者卒中预防 的2b期临床试验申请，这是全球首个于心房颤动临床试验中的小干扰核酸 XI凝血因子抑制剂，标志着siRNA药物在抗凝疗法领域临床开发的重要里程碑。本研究为本公司涵盖多个已规划的针对多种血栓栓塞性心血管适应症的2b期研究的一部分。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","06938":"瑞博生物-B"},"translate_title":"Ruibo Bio-B (06938): Core product VORTOSIRAN completes Phase 2b clinical trial application submission for SPAF indications","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1.5},"content_text":"智通财经APP讯，瑞博生物-B(06938)发布公告，本公司核心产品Vortosiran (RBD4059)已成功向欧洲药品管理局(EMA)递交针对心房颤动患者卒中预防 (SPAF)的2b期临床试验申请(CTA)，这是全球首个于心房颤动(AF)临床试验中的小干扰核酸(siRNA) XI凝血因子(FXI)抑制剂，标志着siRNA药物在抗凝疗法领域临床开发的重要里程碑。本研究为本公司涵盖多个已规划的针对多种血栓栓塞性心血管适应症的2b期研究的一部分。Vortosiran为一种用于治疗血栓性疾病的siRNA药物，其设计通过对FXI精准且持久的抑制，阻断FXI介导的凝血通路，从而抑制FXI凝血活性，在实现强劲血栓栓塞防护的同时，显著降低出血风险，相较于现有抗凝治疗手段，能够在降低出血风险的同时提升患者临床获益。Vortosiran是全球进展最快的靶向FXI的小核酸药物，及截至本公告日期，该产品已完成针对冠状动脉疾病(CAD)的欧洲2a期临床试验。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627464707","isCrawlerRequest":true}